Therapeutic Response Statement (Sensitivity)

This therapeutic response statement supports the relationship that CD20 + status confers therapeutic sensitivity to Cyclophosphamide, Doxorubicin, Etoposide, Prednisolone, Rituximab, Vincristine in patients with Diffuse Large B-Cell Lymphoma.

This statement is based on a regulatory approval from the Health Service Executive:

Treatment of patients with CD20 positive diffuse large B-cell Non Hodgkin's lymphoma (NHL).

Citation

Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf